

**Eligibility criteria**

Patient must:

- a. Be 20 to 75 years of age, with a definitive histological diagnosis of PCa by needle biopsy.
- b. Have intermediate-risk PCa according to D'Amico's stratification
- c. Be previously untreated.
- d. Demonstrate appropriate bone marrow, hepatic and renal function in laboratory tests within two weeks prior to registration.
  - a) Leukocyte count  $\geq 2,000$  / $\mu$ L
  - b) Hemoglobin level  $\geq 10.0$  g/dL
  - c) Platelet count  $\geq 10.0 \times 10^4$  / $\mu$ L
  - d) Serum creatinine level  $\leq 2.0$  mg/dL
  - e) ALT and AST levels  $\leq 100$  IU/L
- e. Have an expected survival time of three months or longer from the start of the treatment.
- f. Agree in writing to participate in this clinical study after receiving adequate explanation.

C  
E  
N  
T  
R  
A  
L  
  
R  
E  
V  
I  
E  
W  
  
O  
F  
  
P  
A  
T  
H  
O  
L  
O  
G  
I  
C  
A  
L  
  
D  
I  
A  
G  
N  
O  
S  
I  
S

R  
A  
N  
D  
O  
M  
I  
Z  
A  
T  
I  
O  
N

3 M  A D T	T P B	9 M  A D T
---------------------------	-------------	---------------------------

3 M  A D T	T P B
---------------------------	-------------